BackgroundMajor depressive disorder (MDD) shows large heterogeneity of symptoms between patients, but within patients, particular symptom clusters may show similar trajectories. While symptom... Show moreBackgroundMajor depressive disorder (MDD) shows large heterogeneity of symptoms between patients, but within patients, particular symptom clusters may show similar trajectories. While symptom clusters and networks have mostly been studied using cross-sectional designs, temporal dynamics of symptoms within patients may yield information that facilitates personalized medicine. Here, we aim to cluster depressive symptom dynamics through dynamic time warping (DTW) analysis.MethodsThe 17-item Hamilton Rating Scale for Depression (HRSD-17) was administered every 2weeks for a median of 11weeks in 255 depressed inpatients. The DTW analysis modeled the temporal dynamics of each pair of individual HRSD-17 items within each patient (i.e., 69,360 calculated "DTW distances"). Subsequently, hierarchical clustering and network models were estimated based on similarities in symptom dynamics both within each patient and at the group level.ResultsThe sample had a mean age of 51 (SD 15.4), and 64.7% were female. Clusters and networks based on symptom dynamics markedly differed across patients. At the group level, five dynamic symptom clusters emerged, which differed from a previously published cross-sectional network. Patients who showed treatment response or remission had the shortest average DTW distance, indicating denser networks with more synchronous symptom trajectories.ConclusionsSymptom dynamics over time can be clustered and visualized using DTW. DTW represents a promising new approach for studying symptom dynamics with the potential to facilitate personalized psychiatric care. Show less
Hebbrecht, K.; Stuivenga, M.; Birkenhager, T.; Mast, R.C. van der; Sabbe, B.; Giltay, E.J. 2020
Background:Although differences in symptom profiles and outcome between depressive patients with an underlying major depressive disorder (MDD) and bipolar depression (BD) have been reported,... Show moreBackground:Although differences in symptom profiles and outcome between depressive patients with an underlying major depressive disorder (MDD) and bipolar depression (BD) have been reported, studies with sequential short-interval assessments in a real-life inpatient setting are scarce.Objectives:To examine potential differences in symptom profile and course of depressive symptomatology in depressive inpatients with underlying MDD and BD.Methods:A cohort of 276 consecutive inpatients with MDD (n= 224) or BD (n= 52) was followed during their hospitalization using routine outcome monitoring (ROM), which included a structured diagnostic interview at baseline (Mini-International Neuropsychiatric Interview Plus [MINI-Plus]) and repeated 17-item Hamilton Depression Rating Scale every 2 weeks. MDD and BD were compared regarding their symptom profiles and time to response and remission. Furthermore, the concordance between the MINI-Plus and clinical diagnosis was analyzed.Results:Patients were on average 52 and 47 years old in the MDD and BD group, respectively, and 66 versus 64% were female. Compared to patients with BD, patients with MDD scored higher on weight loss (p= 0.02), whereas the BD group showed a higher long-term likelihood of response (hazard ratio = 1.93, 95% confidence interval 1.16-3.20,pfor interaction with time = 0.04). Although the same association was seen for remission, the interaction with time was not significant (p= 0.48). Efficiency between the MINI-Plus and clinical diagnosis of BD was high (0.90), suggesting that the MINI-Plus is an adequate ROM diagnostic tool.Conclusions:In routine clinical inpatient care, minor differences in the symptom profile and the course of depressive symptomatology may be helpful in distinguishing MDD and BD, particularly when using sequential ROM assessments. Show less
Stuivenga, M.; Giltay, E.J.; Cools, O.; Roosens, L.; Neels, H.; Sabbe, B. 2019
ABSTRACTIntroduction: Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD) significantlycontribute to the global burden of disease. Vilazodone, a combined serotonin reuptake inhibitor... Show moreABSTRACTIntroduction: Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD) significantlycontribute to the global burden of disease. Vilazodone, a combined serotonin reuptake inhibitor and5-HT1A partial agonist, is an approved therapy for the treatment of MDD and which has been furtherinvestigated for GAD.Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone andprovides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxietydisorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the CochraneLibrary.Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However,vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclearwhether the drug’s dual mechanism of action provides greater efficacy than prevailing treatmentoptions. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety inlarger and more diverse populations. Although vilazodone may have an additional advantage for thetreatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacyover and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodoneshould be considered as a second- or third-line treatment option for MDD and GAD. Show less
